A new treatment for solid tumors that have spread
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called Dato-DXd in people with various solid tumors. It may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to provide a sample of your tumor tissue (from an old biopsy or a new one).
- You should be physically active and able to care for yourself (ECOG score 0 or 1).
- You must not have serious ongoing health problems, like uncontrolled heart disease or infections.
- You must not have had lung inflammation that required steroids, and no current lung inflammation.
- You must not have cancer that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
This trial is testing a new drug combination for advanced bladder cancer that has grown despite previous treatment. It pairs a targeted therapy (datopotamab deruxtecan) with chemotherapy, and the goal is to see if it can slow down or stop the cancer better than standard chemo alone.
This trial tests a new drug called LY4052031 for people with advanced or metastatic cancers, especially bladder cancer. The drug aims to slow or stop tumor growth. Doctors will check if it is safe and how well it works.
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.